NO306534B1 - Anvendelsen av 2-amino-6-trifluormetoksybenzotiazol (Riluzol) for fremstilling av et medikament for anvendelse ved behandling av motorneuron-sykdommer - Google Patents

Anvendelsen av 2-amino-6-trifluormetoksybenzotiazol (Riluzol) for fremstilling av et medikament for anvendelse ved behandling av motorneuron-sykdommer

Info

Publication number
NO306534B1
NO306534B1 NO19943256A NO943256A NO306534B1 NO 306534 B1 NO306534 B1 NO 306534B1 NO 19943256 A NO19943256 A NO 19943256A NO 943256 A NO943256 A NO 943256A NO 306534 B1 NO306534 B1 NO 306534B1
Authority
NO
Norway
Prior art keywords
medicament
amino
manufacture
treatment
motor neuron
Prior art date
Application number
NO19943256A
Other languages
English (en)
Norwegian (no)
Other versions
NO943256L (no
NO943256D0 (no
Inventor
Erik Louvel
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9427427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO306534(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO943256L publication Critical patent/NO943256L/no
Publication of NO943256D0 publication Critical patent/NO943256D0/no
Publication of NO306534B1 publication Critical patent/NO306534B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)
  • Percussion Or Vibration Massage (AREA)
NO19943256A 1992-03-06 1994-09-02 Anvendelsen av 2-amino-6-trifluormetoksybenzotiazol (Riluzol) for fremstilling av et medikament for anvendelse ved behandling av motorneuron-sykdommer NO306534B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9202696A FR2688138B1 (fr) 1992-03-06 1992-03-06 Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
PCT/FR1992/000992 WO1993017683A1 (fr) 1992-03-06 1992-10-22 Application de l'amino-2 trifluoromethoxy-6 benzothiazole (riluzole) pour obtenir un medicament destine au traitement des maladies du motoneurone

Publications (3)

Publication Number Publication Date
NO943256L NO943256L (no) 1994-09-02
NO943256D0 NO943256D0 (no) 1994-09-02
NO306534B1 true NO306534B1 (no) 1999-11-22

Family

ID=9427427

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19943256A NO306534B1 (no) 1992-03-06 1994-09-02 Anvendelsen av 2-amino-6-trifluormetoksybenzotiazol (Riluzol) for fremstilling av et medikament for anvendelse ved behandling av motorneuron-sykdommer

Country Status (22)

Country Link
US (1) US5527814A (de)
EP (2) EP0558861A1 (de)
JP (1) JP2713384B2 (de)
KR (1) KR100190296B1 (de)
AT (1) ATE149833T1 (de)
AU (1) AU666150B2 (de)
CA (1) CA2117466C (de)
CZ (1) CZ281293B6 (de)
DE (1) DE69218255T2 (de)
DK (1) DK0627919T3 (de)
ES (1) ES2098558T3 (de)
FR (1) FR2688138B1 (de)
GR (1) GR3022797T3 (de)
HU (1) HU217130B (de)
IL (1) IL103493A (de)
MX (1) MX9206109A (de)
NO (1) NO306534B1 (de)
RU (1) RU2110260C1 (de)
SK (1) SK279046B6 (de)
UA (1) UA41879C2 (de)
WO (1) WO1993017683A1 (de)
ZA (1) ZA928213B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
ES2159362T3 (es) * 1995-10-26 2001-10-01 Sanofi Synthelabo Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
EP0999204B1 (de) 1997-07-25 2004-10-13 Nippon Kayaku Kabushiki Kaisha Verbindungen zur förderung der neuronendifferenzierung
CA2317811A1 (en) * 1998-01-09 1999-07-15 Mor-Research Applications Ltd. Treatment of dyskinesias
US6417210B1 (en) 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
FR2785808B1 (fr) * 1998-11-13 2002-12-06 Aventis Laboratoire Association riluzole et alpha-tocopherol
US6872739B1 (en) 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
JP2003522121A (ja) * 1999-06-04 2003-07-22 フェレニヒング フォール クリステレイク ウェテンスハッペリキク オンデルウェイス 多発性硬化症の処置のためのリルゾールの使用
JP2001021609A (ja) * 1999-07-07 2001-01-26 Mitsubishi Electric Corp 半導体集積回路の検査方法
DE19940524C2 (de) * 1999-08-26 2003-06-18 Karl-Heinz Lenzkes Fahrzeugrad, insbesondere für Personenkraftfahrzeuge
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
US6964982B2 (en) 2000-04-20 2005-11-15 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
WO2002034264A1 (en) * 2000-10-24 2002-05-02 Mitsubishi Pharma Corporation Remedies for amyotrophic lateral sclerosis (als)
WO2002042842A2 (en) * 2000-11-22 2002-05-30 Allergan, Inc. A high-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels
US6479458B1 (en) 2001-11-08 2002-11-12 Allergan, Inc. Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
US7361478B2 (en) * 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
EP1551793B1 (de) * 2002-06-19 2016-01-20 AmKor Pharma, Inc. Tetrafluorbenzylderivate und diese enthaltende pharmazeutische zusammensetzung zur prävention und behandlung akuter und chronischer neurodegenerativer erkrankungen des zentralen nervensystems
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
EP1883619B8 (de) * 2005-05-25 2013-05-01 JW Pharmaceutical Corporation Verfahren zur herstellung einer substituierten tetrafluorbenzylanilinverbindung und deren pharmazeutisch zugelassenen salzen
US20070298129A1 (en) * 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
EP1924326B1 (de) 2005-08-25 2016-10-12 Steven Michael Weiss Reduzierung von myokard-schaden und inzidenz von arrhythmien durch verlust, verringerung oder unterbrechung des koronaren blutflusses
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
JP5110536B2 (ja) 2006-07-19 2012-12-26 学校法人日本医科大学 筋萎縮性側索硬化症治療薬
JP2010504338A (ja) * 2006-09-20 2010-02-12 メディベイション ニューロロジー， インコーポレイテッド 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
KR100852962B1 (ko) * 2007-11-12 2008-08-20 주식회사 뉴로테크 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
EP2228055A1 (de) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Flüssige Riluzol-Emulsionen
EP2228054A1 (de) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Wässrige Riluzol-Suspensionen
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2011074690A1 (en) 2009-12-14 2011-06-23 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
WO2012029994A1 (en) 2010-09-02 2012-03-08 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US10357497B2 (en) * 2012-06-23 2019-07-23 Biohaven Pharmaceutical Holding Company Limited Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
CA3132310C (en) 2012-08-07 2024-01-09 Children's Medical Center Corporation Potassium channel openers for treating neurodegenerative diseases
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
DK3033081T3 (da) 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
EP3038467B1 (de) 2013-08-13 2020-07-29 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von plasmazellenerkrankungen und prolymphozytischen b-zellen-erkrankungen
US20150210679A1 (en) * 2014-01-28 2015-07-30 Northwestern University Small molecule inhibitors of superoxide dismutase expression
CN107530430A (zh) 2015-01-13 2018-01-02 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
MA48781A (fr) 2017-06-02 2020-04-08 Juno Therapeutics Inc Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
JP2020526194A (ja) 2017-06-29 2020-08-31 ジュノー セラピューティクス インコーポレイテッド 免疫療法薬と関連する毒性を評価するためのマウスモデル
US10322114B2 (en) * 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
PT3886875T (pt) 2018-11-30 2024-06-27 Juno Therapeutics Inc Métodos para tratamento utilizando terapia celular adotiva
CN113692285A (zh) 2018-11-30 2021-11-23 朱诺治疗学股份有限公司 在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
MX2022006715A (es) 2019-12-06 2022-09-23 Juno Therapeutics Inc Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
JPWO2023238869A1 (de) 2022-06-07 2023-12-14

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
FR2619713B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
US5236940A (en) * 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
DE68903484T2 (de) * 1988-12-15 1993-03-18 Rhone Poulenc Sante 2-imino-6-polyfluoralkoxy-benzothiazol-derivate, verfahren zu deren herstellung und arzneimittel, die sie enthalten.
FR2649702B1 (fr) * 1989-07-13 1991-11-22 Rhone Poulenc Sante Derives d'alkylimino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2662160B1 (fr) * 1990-05-18 1992-07-24 Rhone Poulenc Sante Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant.
FR2663029B1 (fr) * 1990-06-07 1992-07-31 Rhone Poulenc Sante Derives de benzothiazole, leur preparation et les medicaments les contenant.

Also Published As

Publication number Publication date
JPH07504655A (ja) 1995-05-25
NO943256L (no) 1994-09-02
JP2713384B2 (ja) 1998-02-16
IL103493A (en) 1996-07-23
SK104794A3 (en) 1995-05-10
EP0627919A1 (de) 1994-12-14
UA41879C2 (uk) 2001-10-15
CA2117466C (fr) 2000-01-25
AU666150B2 (en) 1996-02-01
HUT70946A (en) 1995-11-28
SK279046B6 (sk) 1998-06-03
NO943256D0 (no) 1994-09-02
DE69218255D1 (de) 1997-04-17
US5527814A (en) 1996-06-18
CZ281293B6 (cs) 1996-08-14
GR3022797T3 (en) 1997-06-30
KR950700060A (ko) 1995-01-16
AU2948292A (en) 1993-10-05
FR2688138B1 (fr) 1995-05-05
DK0627919T3 (da) 1997-05-12
HU9402558D0 (en) 1994-11-28
CZ212094A3 (en) 1994-12-15
IL103493A0 (en) 1993-03-15
FR2688138A1 (fr) 1993-09-10
ES2098558T3 (es) 1997-05-01
DE69218255T2 (de) 1997-09-11
EP0558861A1 (de) 1993-09-08
KR100190296B1 (ko) 1999-06-01
EP0627919B1 (de) 1997-03-12
ATE149833T1 (de) 1997-03-15
RU2110260C1 (ru) 1998-05-10
ZA928213B (en) 1993-04-30
CA2117466A1 (fr) 1993-09-16
RU94041223A (ru) 1996-10-20
WO1993017683A1 (fr) 1993-09-16
HU217130B (hu) 1999-11-29
MX9206109A (es) 1993-09-01

Similar Documents

Publication Publication Date Title
NO306534B1 (no) Anvendelsen av 2-amino-6-trifluormetoksybenzotiazol (Riluzol) for fremstilling av et medikament for anvendelse ved behandling av motorneuron-sykdommer
NO981911D0 (no) Anvendelse av rhodaninderivater for fremstilling av et medikament for behandling av Alzheimer's sykdom
AU7005694A (en) Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism
TW229156B (de)
ES2166381T3 (es) Tratamiento de enfermedades vasculares hiperproliferativas.
AU6143994A (en) Use of lamotrigine for treating aids-related neural disorders
FI933902A7 (fi) Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
ES2089136T3 (es) Tratamiento de enfermedades inflamatorias con la ayuda de derivados 15-ceto-prostaglandinas.
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
AU2143388A (en) Use of 2-amino-6-(trifluoromethoxy)benzothiazole for the treatment of schizophrenia
AU8505991A (en) Use of compositions containing 2-(6'-substituted-2'-naphthyl)-acetic acid derivatives for the treatment of respiratory disorders
FI925544A7 (fi) Bentsoehappojohdannaisia leukotrieeniin liittyvien sairauksien hoitami seen
EP0454429A3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
EP0642338A1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit.
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
ZA944671B (en) Medicaments for the treatment of inflammatory diseases
BG49072A1 (en) Anti- influenza remedy
FR2700113B1 (fr) Utilisation de l'Idazoxan et ses dérivés pour la fabrication de médicaments destinés au traitement des maladies neurodégénératives et en particulier l'évolution de la maladie d'Alzheimer.
RU94001222A (ru) Способ лечения воспаленных тканей организма

Legal Events

Date Code Title Description
MK1K Patent expired